Change in the Board of Directors of FluoGuide
Copenhagen, Denmark, 25 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the chairman of the Board of Directors, Arne Ferstad, will not stand for re-election at the upcoming Annual General Meeting
Arne Ferstad, the Chairman of the Board of Directors, has notified FluoGuide that he will not stand for re-election at the upcoming annual general meeting on the 9th of February, 2021, for personal reasons.
“I would like to thank Arne for his great contribution to FluoGuide since the very beginning. It has been a pleasure working together with Arne over these last years, and I wish him the very best” says Morten Albrechtsen, CEO.
The other members of the Board of Directors are Lisa Micaela Sjokvist, Shomit Ghose, Peter Mørch Eriksen and Andreas Kjær, who are all proposed to be re-elected at the Annual General Meeting on the 9th of February 2021.
This disclosure contains information that Fluoguide is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-01-2021 13:55 CET.
Morten Albechtsen, CEO
+45 24 25 62 66
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma including glioblastoma.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.